Identification of Risk Factors Parkinson’s Disease by Convergence Strategy

Overview

Using this convergence approach from a limited group of subjects with non-diseased controls, patients with Parkinson's disease or related diseases, we will be able to limit the number of potential genes of specific susceptibility to Parkinson disease. These genes will then be studied using a case-control genetic epidemiology approach. The risk of developing the disease will then be evaluated according to clinical, biological and environmental variables collected in Parkinson's subjects and healthy controls in the second group of subjects. The specificity of the genetic associations found will be evaluated in subjects with Parkinson's disease.

Full Title of Study: “Identification of Risk Factors Parkinson’s Disease by Convergence Strategy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2024

Arms, Groups and Cohorts

  • Controls
    • This group will include “healthy” person.
  • Parkinson’s patient
    • This group will include Parkinsonian patients
  • patients with a related disease.
    • This group will include patients with a related disease.

Clinical Trial Outcome Measures

Primary Measures

  • Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson’s disease
    • Time Frame: through study completion, an average of 10 years
    • the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson’s disease.

Participating in This Clinical Trial

Inclusion Criteria

Inclusion criteria for Parkinson's patients and "related diseases" controls:

  • Parkinsonian patients meeting the Gelb criteria
  • Patients with other neurodegenerative disease (such as other Parkinson syndrome or synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia, Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's Disease).
  • Woman of childbearing age having an effective means of contraception.
  • Informed consent signed by the subject or his legal representative.
  • For demented subjects coming for consultation or day hospitalization with an accompanying person, signature of the legal representative.

Criteria for inclusion of non-ill controls:

  • Absence of rest trembling, bradykinesia and stiffness
  • MMSE (Mini Mental State Examination) greater than 25
  • Woman of childbearing age having an effective means of contraception.
  • subject having signed the informed consent.
  • No family history of neurodegenerative disease that started before age 70. These controls will not present any Parkinsonian signs during the clinical evaluation. They may have functional disabilities whose cause is known and unrelated to a neurodegenerative disease with a cognitive function measurement greater than 25 in the MMSE test.

Exclusion Criteria

  • Criteria for non-inclusion of patients:
  • Clinical criteria for exclusion of the diseases described
  • Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Criteria for non-inclusion of non-ill controls:

  • Functional discomfort in daily life of unknown cause
  • MMSE less than 25
  • Participation in another therapeutic trial or in the exclusion period of a previous clinical trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Hospital, Lille
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alain DESTEE, MD, PhD, Principal Investigator, University Hospital, Lille
  • Overall Contact(s)
    • Alain DESTEE, MD,PhD, alain.destee@chru-lille.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.